Neurogene
NGNE
46 hedge funds and large institutions have $306M invested in Neurogene in 2016 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 2 closing their positions.
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
246% more call options, than puts
Call options by funds: $882K | Put options by funds: $255K
200% more capital invested
Capital invested by funds: $102M → $306M (+$204M)
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
35% more funds holding
Funds holding: 34 → 46 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$28.1M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$5.04M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$2.52M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$1.6M |
| 2 |
Millennium Management
New York
|
-$364K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$240K |
| 4 |
RA
Royce & Associates
New York
|
-$202K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$24.8K |
NGNE Hedge Fund Activity: Q3 2016 in Review
46 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2016, worth a combined $306M — up 200% from $102M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new NGNE positions and 2 closed out — a net gain of 12 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $32.9M. The largest seller was Nexthera Capital, cutting an estimated $1.6M.
- 46 institutional investors held Neurogene (NGNE) as of Q3 2016, up from 34 in Q2 2016.
- Funds reported $306M of Neurogene stock for Q3 2016, up 200% quarter-over-quarter.
- 14 funds opened new Neurogene positions in Q3 2016 and 2 closed out, a net change of +12 holders.
- The largest Neurogene buyer in Q3 2016 was T. Rowe Price Associates, an estimated $32.9M added.
- The largest Neurogene seller in Q3 2016 was Nexthera Capital, an estimated $1.6M sold.
Based on aggregated 13F filings for Q3 2016.